Hinweis-Modus ist eingeschaltet Ausschalten

FTXH - First Trust Nasdaq Pharmaceuticals ETF (USD) (US33738R8372)

The comparsion limit has been reached: only 5 tools has been added. To add a new one, please remove one of the existing tools.
 
(%)
US33738R8372
FTXH ISIN
Exchange Traded Funds (ETF)
Fondstyp
First Trust
Anbieter
38,59 USD
NAV pro Aktie | 17/07/2026
20/09/2016
Startdatum
4 Wiederholungen pro Jahr
Ausschüttung von Dividenden
CEOXMX
CFI
FTXH
Ticker
Formed
Status
Equity
Investitionsobjekt
Healthcare
Sektor
USA
Geographie
Nasdaq US Smart Pharmaceuticals Index
Benchmark
0.6 %
Gesamtkostenquote
37,89 Mio. USD
Gesamtes Fondsvermögen | 15/07/2026
Nein
UCITS

Rendite auf 17/07/2026, NASDAQ

  • YTD
    1,9 %
  • 1M
    -3,36 %
  • 3M
    -4,14 %
  • 6M
    6,24 %
  • 1J
    35,3 %
  • 3J
    33,95 %
  • 5J
    36,59 %
  • 10J
    -
Zum Börsenpreis einschliesslich Einkommenszahlungen

Letzte Daten zum
Zum Vergleichen hinzufügen

Kurse (FTXH)

Entdecken Sie die umfangreichste Datenbank

1 000 000

Anleihen weltweit

100 000

Aktien

175 910

ETF & Funds

100 000

Indizes

Verwalten Sie Ihr Portfolio auf effizienteste Weise

  • Bond-Screener
  • Watchlist
  • Excel-Add-In

Kurs-Dynamik

FTXH profile

The First Trust Nasdaq Pharmaceuticals ETF (USD) is a(n) Equity Exchange Traded Funds (ETF) seeks to invest in Healthcare sector located in USA. The First Trust fund’s base currency is USD and the share class was registered 20.09.2016 with unique ISIN - US33738R8372. Main exchange is NASDAQ and ticker symbol is FTXH. The total expense ratio is 0.6%. The First Trust Nasdaq Pharmaceuticals ETF (USD) pays dividends 4 time(s) per year.

Struktur FTXH auf 17/07/2026

Wertpapier Wertpapier
Eli Lilly and Company 7,6%
AbbVie Inc. 7,44%
Merck & Co., Inc. 6,98%
Johnson & Johnson 6,91%
Bristol-Myers Squibb Company 6,61%
Viatris Inc. 3,93%
Biogen Inc. 3,64%
Cardinal Health, Inc. 3,38%
Vertex Pharmaceuticals Incorporated 3,31%
Amgen Inc. 3,2%
Pfizer Inc. 3,07%
Gilead Sciences, Inc. 3,06%
Regeneron Pharmaceuticals, Inc. 2,94%
United Therapeutics Corporation 2,68%
Jazz Pharmaceuticals Plc 2,54%
Incyte Corporation 2,46%
Illumina, Inc. 2,1%
Zoetis Inc. 1,98%
Exelixis, Inc. 1,76%
Charles River Laboratories International, Inc. 1,46%
Medpace Holdings, Inc. 1,43%
Neurocrine Biosciences, Inc. 1,38%
Alkermes Plc 1,36%
PTC Therapeutics, Inc. 1,31%
Halozyme Therapeutics, Inc. 1,2%
BioMarin Pharmaceutical Inc. 1,16%
Spyre Therapeutics, Inc. 1,09%
Twist Bioscience Corporation 0,93%
10X Genomics, Inc. (Class A) 0,89%
Travere Therapeutics, Inc. 0,89%
Elanco Animal Health Incorporated 0,87%
TG Therapeutics, Inc. 0,85%
Guardant Health, Inc. 0,77%
Amneal Pharmaceuticals, Inc. 0,71%
Ligand Pharmaceuticals Inc. (Class B) 0,71%
Protagonist Therapeutics, Inc. 0,71%
Arcus Biosciences, Inc. 0,63%
Arrowhead Pharmaceuticals, Inc. 0,6%
Krystal Biotech, Inc. 0,6%
Mirum Pharmaceuticals, Inc. 0,6%
Kymera Therapeutics, Inc. 0,59%
Roivant Sciences Ltd. 0,56%
Moderna, Inc. 0,54%
ACADIA Pharmaceuticals Inc. 0,49%
Arcutis Biotherapeutics, Inc. 0,49%
Supernus Pharmaceuticals, Inc. 0,41%
Alnylam Pharmaceuticals, Inc. 0,37%
Tarsus Pharmaceuticals, Inc. 0,37%
Ionis Pharmaceuticals, Inc. 0,31%
US Dollar 0,14%
Andere - %

Andere ETFs und Fonds dieses Anbieters

Ähnliche Etf & Fonds

  • {{ item.etf.ttl }}
    {{ item.nav_usd }} Mio.
    NAV
    {{ item.expense_ratio }}
    Gesamtkostenquote
Sie müssen sich registrieren , um Zugriff zu erhalten.